|
[1]OTT JJ, STEVEN GA, GROEGER J, et al.Global epidemiology of hepatitis B virus infection:New estimates of age-specific HBsAg seroprevalence and endemicity[J].Vaccine, 2012, 30 (12) :2212-2219.
|
|
[2] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al.Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64 (1) :73-84.
|
|
[3]PAIS R, RUSU E, RATZIU V.The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease[J].Clin Liver Dis, 2014, 18 (1) :165-178.
|
|
[4]LI Z, XUE J, CHEN P, et al.Prevalence of non-alcoholic fatty liver disease in mainland of China:A meta-analysis of published studies[J].J Gastroenterol Hepatol, 2014, 29 (1) :42-51.
|
|
[5]WANG H, FAN JT, CHANG CF.Clinical and pathological analysis of 75 cases of chronic hepatitis B complicated with fatty liver[J].Chin J Ctrl Endem Dis, 2017, 32 (11) :1237-1238. (in Chinese) 王浩, 范敬婷, 常彩芳.慢性乙型肝炎合并脂肪肝75例临床与病理学探析[J].中国地方病防治杂志, 2017, 32 (11) :1237-1238.
|
|
[6]WANG MF, LIN S, WU YL, et al.The correlation between fatty liver disease and serum and histological viral parameters in patients with chronic hepatitis B[J].Chin J Infect Dis, 2016, 34 (3) :141-145. (in Chinese) 王明芳, 林苏, 吴银莲, 等.慢性乙型肝炎患者肝脂肪变性与血清、肝组织病毒因素的关系[J].中华传染病杂志, 2016, 34 (3) :141-145.
|
|
[7]ZHANG ZQ, WANG GS, KANG KF, et al.Analysis of highrisk groups and predictive factors for hepatic steatosis in patients with chronic hepatitis B[J].J Clin Hepatol, 2015, 31 (7) :1123-1125. (in Chinese) 张志侨, 王功遂, 康凯夫, 等.慢性乙型肝炎患者肝脏脂肪变性的高危人群和预测因素分析[J].临床肝胆病杂志, 2015, 31 (7) :1123-1125.
|
|
[8]WANG XL, CHEN XJ.The relationship between serum lipid and HBV DNA in patients with chronic hepatitis B complicated with hepatic steatosis[J].Chin Hepatol, 2014, 19 (2) :115-118. (in Chinese) 王晓霖, 陈秀记.慢性乙型肝炎合并肝脂肪变患者血脂与HBVDNA的关系[J].肝脏, 2014, 19 (2) :115-118.
|
|
[9]NAU AL, SOARES JC, SHIOZAWA MB, et al.Clinical and laboratory characteristics associated with dyslipidemia and liver steatosis in chronic HBV carriers[J].Rev Soc Bras Med Trop, 2014, 47 (2) :158-164.
|
|
[10]FAN JG, CHEN GF, JI D, et al.Long-term disease progression and prevalence of metabolic syndrome in chronic hepatitis B patients with comorbid nonalcoholic fatty liver disease[J].Hepatology, 2016, 64 (S1) :538a.
|
|
[11]YILMAZ B, KOKLU S, BUVUKBAYRAM H, et al.Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis[J].Afr Health Sci, 2015, 15 (3) :714-718.
|
|
[12]PIRGON O, BILGIN H, TOLU I, et al.Correlation of insulin sensitivity with bone mineral status in obese adolescents with non-alcoholic fatty liver disease[J].Clin Endocrinol (Oxf) , 2011, 75 (2) :189-195.
|
|
[13]WEI JP, ZHENG HJ, ZHAO J, et al.Mechanisms of diabetes mellitus complicated with liver disease and intervention of traditional Chinese medicine[J].J Med Res, 2017, 46 (9) :1-4. (in Chinese) 魏军平, 郑慧娟, 赵静, 等.糖尿病合并肝病机制研究及中药干预[J].医学研究杂志, 2017, 46 (9) :1-4.
|
|
[14]DAI FH, ZENG WQ, JIANG CY.Assessment of the relationship between expression of insulin receptor substrate-1 (IRS-1) and tyrosine phosphorylation and insulin resistance in hepatic tissue of patients with chronic hepatitis B virus infection[J].China JModern Med, 2012, 22 (29) :66-70. (in Chinese) 戴福宏, 曾维琼, 江萃英.肝组织胰岛素受体底物1表达及其酪氨酸磷酸化与慢性乙型肝炎病毒感染者胰岛素抵抗的关系[J].中国现代医学杂志, 2012, 22 (29) :66-70.
|
|
[15]ZHANG XH, PENG YZ.Value of serum apolipoprotein level in clinical judgment of liver injury in chronic hepatic disease of HBV[J].Chin Hepatol, 2016, 21 (10) :850-852. (in Chinese) 张晓华, 彭雁忠.血清载脂蛋白水平用于临床判断HBV慢性肝病肝损伤程度的价值[J].肝脏, 2016, 21 (10) :850-852.
|
|
[16]WANG D.Hepatitis B virus involved in hepatic steatosis via effect on Apolipoprotein and NQO1 expression[D].Fuzhou:Fujian Medical University, 2013. (in Chinese) 王栋.乙型肝炎病毒介导载脂蛋白和NQO1对肝细胞脂肪化的作用及机制研究[D].福州:福建医科大学, 2013.
|
|
[17]WANG FB, ZHU CL, LIU X, et al.HBV inhibits apoB production via the suppression of MTP expression[J].Lipids Health Dis, 2011, 10:207.
|
|
[18]YU J, WU XX, WANG CX, et al.NQO1 dependent non-canonical necroptosis mediated by ROS and RIP1/RIP3 in parallel in glioma cancer cells[J].Chin J Pharmacol Toxicol, 2018, 4:326-327.
|
|
[19]YE Y, YU J.Adiponectin level, its gene polymorphism and nonalcoholic fatty liver disease[J].Basic Clin Med, 2014, 34 (9) :1285-1288. (in Chinese) 叶瑶, 于健.脂联素及基因多态性与非酒精性脂肪肝的研究进展[J].基础医学与临床, 2014, 34 (9) :1285-1288.
|
|
[20]SHEN X, LI H, LI W, et al.Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR1 and AdipoR2in coronary arteries and coronary VSMCs[J].Mol Cell Endocrinol, 2012, 363 (1-2) :27-35.
|
|
[21]PENG H, YANG J, MAI RZ, et al.Relationship between serum adiponectin level and metabolic indices in patients with chronic hepatitis B[J].J Clin Hepatol, 2014, 30 (4) :354-356. (in Chinese) 彭红, 杨健, 麦润章, 等.慢性乙型肝炎患者血清脂联素水平及其与代谢指标的关系[J].临床肝胆病杂志, 2014, 30 (4) :354-356.
|
|
[22]WANG YF.Advances in HBV-related liver diseases induced by HBx protein and TGF-beta[J].Chongqing Med, 2017, 10 (28) :4011-4012, 4032. (in Chinese) 王玉凤.HBx蛋白与TGF-β致HBV相关性肝病的研究进展[J].重庆医学, 2017, 10 (28) :4011-4012, 4032.
|
|
[23]ZHAO HJ, LI L, WEI WH, et al.Relativity between the gene polymorphisms of LXR and metabolic syndrome[J].Chin JClin Pharmacol Ther, 2017, 22 (6) :713-720. (in Chinese) 赵慧佳, 李玲, 魏婉慧, 等.肝X受体的基因多态性与代谢类疾病的相关性[J].中国临床药理学与治疗学, 2017, 22 (6) :713-720.
|
|
[24]HSIEH J, KOSEKI M, MOLUSKY MM, et al.TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis[J].Nature, 2016, 535 (7611) :303-307.
|
|
[25]QIAO H, LIU QP.Progress in the study of sterol regulatory element binding protein-1 signal pathway[J].Chin J Cell Biol, 2015, 37 (10) :1432-1440. (in Chinese) 乔辉, 刘庆平.固醇调节元件结合蛋白-1信号通路研究进展[J].中国细胞生物学学报, 2015, 37 (10) :1432-1440.
|
|
[26]ZHANG C, CHEN X, ZHU RM, et al.Endoplasmic reticulum stress is involved in hepatic SREBP-1c activation and lipid accumulation in fructose-fed mice[J].Toxicol Lett, 2012, 212 (3) :229-240.
|
|
[27]SHI YX, HUANG CJ, YANG ZG.Impact of hepatitis B virus infection on hepatic metabolic signaling pathway[J].World JGastroenterol, 2016, 22 (36) :8161-8167.
|
|
[28]BONDINI S, KALLMAN J, WHEELER A, et al.Impact of non-alcoholic fatty liver disease on chronic hepatitis B[J].Liver International, 2007, 27 (5) :607-611.
|
|
[29]HAWKINS PT, STEPHENS LR.PI3K signalling in inflammation[J].Biochimical Biophysical Acta, 2015, 1851 (6) :882-897.
|
|
[30]OSORIO-FUENTEALBA C, KLIP A.Dissecting signalling by individual Akt/PKB isoforms, three steps at once[J].Biochem J, 2015, 470 (2) :13-16.
|
|
[31]DONG QL, KOU XN, ZHU BZ.Anti-inflammatory effect of insulin and its mechanism[J].Chin J Diabetes, 2018, 26 (2) :156-160. (in Chinese) 董倩兰, 寇小妮, 朱本章.胰岛素的抗炎作用及其机制[J].中国糖尿病杂志, 2018, 26 (2) :156-160.
|
|
[32]BAKAN I, LAPLANTE M.Connecting m TORC1 signaling to SREBP-1c activation[J].Curr Opin Lipidol, 2012, 23 (3) :226-234.
|
|
[33]WANG HW, GAO HL, WEI XX, et al.Up-regulation of IL-12expression in patients with chronic hepatitis B is mediated by the PI3K/Akt pathway[J].Mol Cell Biochem, 2015, 407 (1-2) :135-142.
|
|
[34]OHLSSON E, HASEMANN MS, WILLER A, et al.Initiation of MLL-rear-ranged AML is dependent on C/EBPα[J].J Exp Med, 2014, 211 (1) :5-13.
|
|
[35]YUAN B, WANG Y, CAO HK, et al.Progress of nuclear receptor in nonalcoholic fatty liver disease[J].Central South Pharm, 2018, 16 (5) :674-678. (in Chinese) 苑博, 王宇, 曹后康, 等.核受体在非酒精性脂肪肝中的研究进展[J].中南药学, 2018, 16 (5) :674-678.
|
|
[36]MADSEN MS, SIERSBAK R, BOERGESEN M, et al.Peroxisome proliferator-activated receptorγand C/EBPαsynergistically activate key metabolic adipocyte genes by assisted loading[J].Mol Cell Biol, 2014, 34 (6) :939-954.
|
|
[37]YUE X, WAN CH, ZHAO PW, et al.Hepatitis B virus X protein induces CRT transcription by activating C/EBPα[J].Chin JMicrobiol Immunol, 2016, 36 (10) :740-745. (in Chinese) 乐鑫, 万春辉, 赵培伟, 等.乙肝病毒X蛋白通过激活C/EBPα上调CRT转录[J].中华微生物学和免疫学杂志, 2016, 36 (10) :740-745.
|
|
[38]LI BX, LI JH.The influence of hepatic steatosis on the antiviral efficacy in patients with chronic hepatitis B[J].Contemp Med Forum, 2014, 12 (20) :281-282. (in Chinese) 李保欣, 李俊红.浅谈慢性乙肝患者发生肝脂肪样变对其抗病毒治疗效果的影响[J].当代医药论丛, 2014, 12 (20) :281-282.
|
|
[39]CHEN J.Effect of antiviral therapy with entecavir on the efficacy of different degrees of nonalcoholic fatty liver disease[J/CD].J Clin Med, 2016, 3 (34) :6845. (in Chinese) 陈建.恩替卡韦抗病毒对不同程度非酒精性脂肪性肝病疗效的影响[J/CD].临床医药文献电子杂志, 2016, 3 (34) :6845.
|
|
[40]JIA JL.Effect of hepatic steatosis on antiviral therapy of chron-[[[ic hepatitis B[J].Heilongjiang Med J, 2018, 31 (3) :616-618. (in Chinese) 贾蛟龙.肝脂肪变对慢性乙肝抗病毒治疗效果的影响分析[J].黑龙江医药, 2018, 31 (3) :616-618.
|
|
[41]ATES F, YALNIZ M, ALAN S.Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B[J].World J Gastroenterol, 2011, 17 (40) :4517-4522.
|
|
[42]SHI JP, FAN JG, WU R, et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J].J Gastroenterol Hepatol, 2008, 23 (9) :1419-1425.
|
|
[43]HAN JM, ZHANG YX, LIU ZL, et al.Influence factors of chronic hepatitis B patients complicated with non-alcoholic fatty liver disease[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (2) :51-55. (in Chinese) 韩俊梅, 张燕霞, 刘赵亮, 等.慢性乙型肝炎合并非酒精性脂肪性肝病的影响因素[J/CD].中国肝脏病杂志:电子版, 2017, 9 (2) :51-55.
|
DownLoad: